New Lilly R&D chief planning blitz of drug launches
Dr. Dan Skovronsky needs to deliver on the drugmaker’s audacious goal of launching 20 new medicines by 2023.
Pharmaceutical
Articles
Trial of potential Alzheimer’s treatment shows rare positive results
While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
Lilly unveils new $75M research building in Indianapolis
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
Another experimental Alzheimer’s drug fails as Eli Lilly, Astra halt tests
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
In setback for Lilly, FDA limits dosage, slaps warning on new arthritis drug
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
Gene therapies that could transform diseases get easier FDA path
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
Congress gives dying patients easier access to unproven drugs
President Donald Trump’s interest in the bill stems from a push by Vice President Mike Pence, who championed the initiative when he was governor of Indiana.
Anthem’s pharmacy-benefits-management unit off to bumpy start
Brian Griffin, the leader of Anthem’s new PBM, IngenioRx, quit on May 8 with no warning to become CEO of Michigan-based Diplomat Pharmacy. Now Anthem is scrambling to adjust.
Trump unveils ‘sweeping’ plan to reduce prescription drug prices
President Donald Trump's long-awaited plan to bring down drug prices, unveiled Friday, will mostly spare the pharmaceutical industry he previously accused of "getting away with murder" and instead focus on increasing private competition.
Trump plan for drug prices won’t include direct negotiations
President Donald Trump is set to unveil his long-awaited plan for reducing drug prices after more than a year of bold promises to tackle pharmacy costs that are squeezing millions of Americans.
Crawfordsville startup CorVus fattens pigs for science
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
Drug industry sets lobbying records as pricing pressure looms
The drug industry set several quarterly records for lobbying spending in the first three months of 2018, but Indianapolis-based Eli Lilly and Co. actually reduced lobbying expenditures.
Americans filling far fewer opioid prescriptions, new report says
The number of prescriptions for opioid painkillers filled in the United States fell dramatically last year, showing their biggest drop in 25 years.
Indiana group to create app to teach doctors about opioids
The Richard M. Fairbanks Foundation awarded $230,000 to the Indiana State Medical Association this week to develop the app and an accompanying podcast.
Lilly signs licensing deal with biotech startup for diabetes drug
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
High court asked to take case that could determine size of eye drops
What most people see as an annoyance, some prescription drop users say is grounds for a lawsuit.
Former Lilly CFO Rice to lead CVS Caremark, report says
Derica Rice, 53, one of the nation’s most powerful black executives, retired from Indianapolis-based drugmaker Eli Lilly and Co. in December, after the company passed him over when naming a new CEO.
House rejects GOP bill easing use of unproven drugs
The House rejected legislation Tuesday that would ease how experimental drugs are provided to people with terminal illnesses.
‘Rigged’ system blocks lower-cost drugs, head of FDA says
FDA Commissioner Scott Gottlieb aimed particular criticism at giant pharmacy benefit managers that contract with health plans to administer coverage of drugs, saying the industry’s tactics have stymied cheaper copies of expensive biotechnology drugs.
FDA opens new path for Alzheimer’s therapy as failures mount
The Food and Drug Administration proposal will create new opportunities for drugmakers after repeated failures from companies including Indianapolis-based Eli Lilly and Co.